Subsidies & Funding

We empower medical innovation

Project Management

We manage your EU Horizon 2020 project

Business Strategy

We support successful commercialisation

Funding database

EU & non EU subsidies


Prof. dr. Philippe Lambin received an ERC Advanced Grant of €2.5M to push cancer immunotherapy

April 20 2016

Lung cancer is the most common cause of death from cancer worldwide. Recent breakthroughs in the field of cancer immunotherapy have opened-up new treatment options for patients with lung cancer. 

Despite these developments still a limited number of patients benefit from cancer immunotherapy. The ERC Advanced Grant project HYPOXIMMUNO has been designed to improve the efficacy of cancer immunotherapy. The group of Prof. Lambin will introduce a new paradigm for treating metastatic lung cancer disease through a combination of 1) high precision stereotactic radiotherapy to kill cancer cells and activate the immune system, 2) a hypoxia-activated prodrug to target hypoxic tumour cells resistant to immunotherapy and 3) a promising tumour-specific antibody-based therapy to trigger the immune system, with or without an immune checkpoint inhibitor. The research project has been perfectly summarised in this animation:

(Source: Maastro Clinic)

ttopstart wishes Prof. Lambin and his team good luck with this ambitious project.

Share this

Patrick de Boer, MSc
+31 (0)653897487